Xu Shenjie, Xiang Bin, Ye Lu, Jin Yifeng, Li Jie
Department of General Practice, The First Affiliated Hospital of Soochow University, Suzhou, China.
Department of Respiratory Medicine, Chengdu Sixth People's Hospital, Chengdu, China.
Int J Endocrinol. 2025 May 21;2025:1159707. doi: 10.1155/ije/1159707. eCollection 2025.
Research indicates a strong link between obesity and alterations in thyroid function among patients diagnosed with obstructive sleep apnea-hypopnea syndrome (OSAHS). Our study aims to investigate the thyroid hormone levels in patients with OSAHS combined with obesity. It seeks to elucidate the changes in thyroid hormones and their potential metabolic risks in these patients, thereby further clarifying the role and clinical significance of thyroid function alterations in OSAHS complicated by obesity. One hundred and thirty-four patients were divided into four groups, including the normal group, the obesity group, the OSAHS with the obesity group, and the OSAHS group. Serum levels of free triiodothyronine (FT3), free thyroxine (FT4), and thyroid-stimulating hormone (TSH) were analyzed using electrochemiluminescence immunoassay. Clinical metabolic parameters (total cholesterol [TC], triglycerides [TG], high-density lipoprotein cholesterol [HDL-C], low-density lipoprotein cholesterol [LDL-C]) and sleep respiratory monitoring indicators (apnea-hypopnea index [AHI], longest duration of sleep apnea [TAmax], oxygen desaturation index [ODI], mean oxygen saturation [M-SaO], and lowest oxygen saturation [L-SaO]) were also recorded. The OSAHS with the obesity group demonstrated elevated FT3, TSH, and ODI levels but lower L-SaO level than other groups, and the levels of TG and LDL-C were higher than those in the OSAHS group and the normal group. Additionally, TSH level was positively correlated with LDL-C and BMI, but negatively correlated with L-SaO. In the obesity group, FT3, TSH, TG, ODI, and TAmax levels were higher, while L-SaO and M-SaO were lower than those in the normal group. Patients with both OSAHS and obesity are at higher risk of developing subclinical hypothyroidism, with LDL-C, BMI, and L-SaO levels likely contributing to changes in TSH levels.
研究表明,在被诊断为阻塞性睡眠呼吸暂停低通气综合征(OSAHS)的患者中,肥胖与甲状腺功能改变之间存在密切联系。我们的研究旨在调查合并肥胖的OSAHS患者的甲状腺激素水平。该研究试图阐明这些患者甲状腺激素的变化及其潜在的代谢风险,从而进一步明确甲状腺功能改变在合并肥胖的OSAHS中的作用和临床意义。134名患者被分为四组,包括正常组、肥胖组、合并肥胖的OSAHS组和OSAHS组。采用电化学发光免疫分析法分析血清游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)和促甲状腺激素(TSH)水平。还记录了临床代谢参数(总胆固醇[TC]、甘油三酯[TG]、高密度脂蛋白胆固醇[HDL-C]、低密度脂蛋白胆固醇[LDL-C])和睡眠呼吸监测指标(呼吸暂停低通气指数[AHI]、最长睡眠呼吸暂停持续时间[TAmax]、氧饱和度下降指数[ODI]、平均血氧饱和度[M-SaO]和最低血氧饱和度[L-SaO])。合并肥胖的OSAHS组的FT3、TSH和ODI水平升高,但L-SaO水平低于其他组,且TG和LDL-C水平高于OSAHS组和正常组。此外,TSH水平与LDL-C和BMI呈正相关,但与L-SaO呈负相关。在肥胖组中,FT3、TSH、TG、ODI和TAmax水平较高,而L-SaO和M-SaO低于正常组。同时患有OSAHS和肥胖的患者发生亚临床甲状腺功能减退的风险更高,LDL-C、BMI和L-SaO水平可能导致TSH水平的变化。